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Dupilumab reduces systemic corticosteroid use and 
sinonasal surgery rate in CRSwNP*
Abstract
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease with a high symptom burden 
and poor quality of life. Treatment options include recurrent surgeries and/or frequent systemic corticosteroids (SCS). Dupilu-
mab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4 and interleukin-13, key drivers 
of type 2-mediated inflammation. We report results of pooled analyses from 2 randomised, double-blind, placebo-controlled 
phase 3 studies (SINUS 24 [NCT02912468]; SINUS-52 [NCT02898454]) to evaluate dupilumab effect versus placebo in adults with 
CRSwNP with/without SCS use and sinonasal surgery.
Methodology: SINUS-24 patients were randomised 1:1 to subcutaneous dupilumab 300 mg (n=143) or placebo (n=133) every 
2 weeks (q2w) for 24 weeks. SINUS-52 patients were randomised 1:1:1 to 52 weeks of subcutaneous dupilumab 300 mg q2w 
(n=150), 24 weeks q2w followed by 28 weeks of dupilumab 300 mg every 4 weeks (n=145) or 52 weeks of placebo q2w (n=153).
Results: Dupilumab reduced the number of patients undergoing sinonasal surgery (82.6%), the need for in-study SCS use (73.9%), 
and SCS courses (75.3%). Significant improvements were observed with dupilumab vs placebo regardless of prior sinonasal sur-
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Dupilumab reduces SCS use and surgery in CRSwNP
Introduction
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic 
inflammatory disease of the nose and paranasal sinuses cha-
racterised by symptoms of rhinosinusitis for ≥3 months, nasal 
polyps and sinus disease/involvement(1). CRSwNP is associated 
with a high symptom burden and poor health-related quality of 
life (HRQoL)(2). 
Treatment guidelines for CRSwNP recommend a stepwise 
approach based on disease severity that includes nasal saline 
irrigation and topical/local intranasal corticosteroids (INCS), and 
short courses of oral corticosteroids for uncontrolled severe 
disease(1,3). Patients who are refractory to medical therapy may 
benefit from endoscopic sinus surgery (ESS), although postope-
rative nasal polyp recurrence is common, with reported recur-
rence rates of approximately 40% of patients within 18 months 
of ESS to nearly 80% within 12 years(4–6). The rate of repeated sur-
geries is higher among patients with a more pronounced type 2 
inflammatory signature, which can be identified by asthma and 
non-steroidal anti-inflammatory drug-exacerbated respiratory 
disease (N-ERD) comorbidities or increased eosinophil counts 
and higher interleukin (IL)-5 and immunoglobulin (Ig)E levels in 
nasal or sinus tissue(4,7,8). Common adverse events (AEs) linked to 
prolonged systemic corticosteroid use have been well docu-
mented, along with their associated costs(9–12), highlighting the 
need for corticosteroid-sparing therapies.
Dupilumab is a fully human VelocImmune®-derived monoclonal 
antibody(13,14), that inhibits signalling of both IL-4 and IL-13, key 
and central cytokines involved in type 2-mediated inflamma-
tion(15,16). Dupilumab is the first biologic treatment approved by 
the US Food and Drug Administration, the European Medicines 
Agency and the Japanese Ministry of Health, Labour and Welfare 
as an add-on maintenance treatment in adult patients with 
inadequately controlled CRSwNP(17–19). 
The phase 3 studies SINUS-24 (NCT02912468) and SINUS-52 
(NCT02898454) investigated dupilumab added to a back-
ground of INCS (mometasone furoate nasal spray [MFNS]) in 
severe CRSwNP uncontrolled by standard of care(20). Dupilumab 
significantly improved endoscopic (nasal polyp score [NPS]), 
radiographic (Lund MacKay-CT [LMK-CT] score), clinical (nasal 
congestion [NC], total symptom score and University of Pennsyl-
vania Smell Identification Test [UPSIT] score) and HRQoL outco-
mes (22-item Sino-Nasal Outcome Test [SNOT-22]). Dupilumab 
also improved lung function and asthma control in the subset of 
patients with comorbid asthma. 
These analyses examined a pooled population of patients with 
CRSwNP enrolled in the SINUS-24 and SINUS-52 studies. The 
objective was to  investigate whether dupilumab was superior 
to standard of care in reducing the need for systemic cortico-
steroid (SCS) use or sinonasal surgery, both after SCS use in the 
study and in subgroups of patients with/without prior SCS use 
or sinonasal surgery. 
Materials and methods
Study design 
SINUS-24 and SINUS-52 were randomised, multicentre, double-
blind, placebo-controlled, parallel-group studies assessing 
dupilumab as an add-on treatment to standard of care in adults 
with severe CRSwNP(20). In SINUS-24, patients were randomly 
assigned (1:1) to subcutaneous dupilumab 300 mg or placebo 
every 2 weeks (q2w) for 24 weeks; in SINUS-52, patients were 
randomised (1:1:1) to dupilumab 300 mg q2w for 52 weeks 
(Arm A), to dupilumab 300 mg dosed q2w for 24 weeks followed 
by every 4 weeks (q4w) for the remaining 28 weeks (Arm B) or 
to placebo q2w for 52 weeks (Arm C). During a 4-week run-in 
period, and throughout the trial, patients received 100 µg MFNS 
in each nostril twice daily. Concomitant rescue treatment with 
short courses of SCSs, systemic antibiotics and sinonasal surgery 
was allowed at the investigator’s discretion during the studies. 
At the time of surgery, patients were permanently discontinued 
from study treatment.
The studies were conducted in accordance with the Declaration 
of Helsinki, International Conference on Harmonization Good 
Clinical Practice guidelines and applicable regulatory require-
ments. An independent data and safety monitoring committee 
conducted blinded monitoring of patient safety data, and the 
local institutional review board or ethics committee at each 
study centre oversaw trial conduct and documentation. All 
patients provided written informed consent before participating 
in the trial.
gery or SCS use in nasal polyp, nasal congestion, Lund-MacKay, and Sinonasal Outcome Test (22-items) scores, and the University 
of Pennsylvania Smell Identification Test.
Conclusions: Dupilumab demonstrated significant improvements in disease signs and symptoms and reduced the need for sino-
nasal surgery and SCS use versus placebo in patients with severe CRSwNP, regardless of SCS use in the previous 2 years, or prior 
sinonasal surgery.
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surgery during the study treatment period. The reason for SCS 
use, the annualised SCS dose (mg), and the duration (days) and 
number of SCS courses were also documented. Subgroup ana-
lyses to evaluate efficacy in patients with/without prior surgery 
and in patients with/without prior SCS use were also conducted. 
Sensitivity analyses, including data recorded after SCS use, were 
conducted on the primary endpoints, NPS and NC score and on 
the key secondary endpoint of LMK-CT score. Safety was measu-
red by pooling safety data overall and in patients with/without 
SCS use or sinonasal surgery during treatment.
Statistical analysis
This pooled analysis combined all patients from the 2 studies 
randomised to the dupilumab 300 mg q2w dosing – Arm A over 
the 52-week treatment period and Arm B (first 24 weeks q2w) 
of SINUS-52, and dupilumab arm of SINUS-24. For the placebo 
group, the placebo arms of both SINUS-24 up to Week 24 and 
SINUS-52 up to Week 52 were combined.
The Kaplan-Meier (K-M) method was used to estimate probabi-
lities of events up to Week 52 with the hazard ratio (HR) derived 
from a Cox proportional hazard model with the event of first SCS 
use and/or NP surgery (patients who underwent or planned, 
whichever is earlier) as the response variable and treatment, 
asthma/AERD status, prior surgery history, region (pooled 
country) and study indicator (0 for SINUS-52 and 1 for SINUS-24) 
as covariates. The proportion and time-to-event of patients 
requiring rescue treatment (defined as SCS use or sinonasal 
surgery [actual or planned during the study]) during the treat-
ment period for dupilumab 300 mg q2w versus placebo were 
prespecified, multiplicity-adjusted efficacy endpoints.
For primary and key secondary endpoints, data collected after 
Eligibility criteria and subgroups analysed
Adult patients with CRSwNP who had undergone prior treat-
ment with SCSs (or for whom SCSs were contraindicated or not 
tolerated) in the past 2 years OR who had had prior surgery for 
nasal polyps (NP) were eligible for enrolment if they fulfilled the 
following criteria: had bilateral NP despite treatment with INCS 
for ≥2 months and with a total NPS of ≥5 (out of 8), and ≥2 for 
each nostril; ongoing symptoms of NC/nasal blockade/nasal 
obstruction (for ≥8 weeks before Visit 1 [V1]) with a symptom 
severity score of 2 or 3 (moderate or severe) at V1 and a weekly 
average severity score of >1 at randomisation (V2) AND ≥1 other 
symptom such as reduction in/loss of smell or anterior rhinor-
rhoea/postnasal drip.
Patients were excluded if they had undergone monoclonal an-
tibody and/or immunosuppressive treatment within 2 months, 
or anti-IgE therapy (omalizumab) within 130 days, of screening; 
had undergone sinus surgery (including polypectomy) within 6 
months before screening or sinonasal surgery that structurally 
altered the lateral wall of the nose making the evaluation of 
NPS impossible; or if they had a forced expiratory volume in 1 
second of ≤50% of the predicted normal value.
Patients were stratified at baseline according to the following: 
history of asthma, including aspirin-exacerbated respiratory 
disease (AERD)/N-ERD (yes/no); prior sinonasal surgery (yes/
no); and country. Type of previous sinonasal surgery was not 
specified.
Outcome measures
The effect of dupilumab on the need for SCS use or sinonasal 
surgery was assessed by measuring the proportion of patients 
requiring SCSs or who underwent or planned for sinonasal 
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treatment discontinuation were included. For the purpose of the 
primary analysis, data post-SCS use or sinonasal surgery were 
set to missing and imputed by worst observation carried for-
ward (WOCF); missing data without SCS use or sinonasal surgery 
were imputed by multiple imputation (MI) methods. Each of 
the imputed complete data sets were analysed by fitting an AN-
COVA model with the corresponding baseline value, treatment 
group, prior surgery history, asthma/NSAID-ERD comorbidity 
status and study regions as covariates.
A sensitivity analysis conducted as an ‘as-observed analysis’ 
included data collected after SCS use for any reason and treat-
ment discontinuation but excluded post-NP surgery data.
Results
Study patients and baseline characteristics
A total of 276 patients were randomised into SINUS-24 and 448 
patients were randomised into SINUS 52 (Figure 1).
Baseline characteristics for patients with/without prior SCS use 
and with/without prior sinonasal surgery are outlined in Table 
1. Patient baseline characteristics stratified by treatment group 
are provided in Table E1 of the online repository. A total of 459 
(63.4%) patients had a history of prior sinonasal surgery with a 
mean of approximately 7 years since their most recent surgery. 
The mean number of prior surgeries among these patients was 
1.96. A total of 538 (74.3%) patients had required SCSs during 
the previous 2 years with a mean of around 217 days since 
Table 1. Baseline characteristics for patients with/without prior SCS use or with/without prior sinonasal surgery.
















Age, mean (SD), y 50.79 (12.87) 53.15 (12.57) 51.38 (12.61) 51.42 (13.22)
Male sex, n (%) 338 (62.8) 99 (53.2) 268 (58.4) 169 (63.8)
NP duration, mean (SD), y 10.17 (9.29) 13.41 (9.49) 14.20 (9.62) 5.53 (6.02)
Bilateral endoscopic NPS, mean (SD), 0–8† 6.01 (1.26) 5.85 (1.22) 5.86 (1.26) 6.15 (1.20)
Nasal congestion (AM) score, mean (SD), 0–3† 2.42 (0.57) 2.34 (0.61) 2.44 (0.56) 2.33 (0.60)
SNOT-22 total score, mean (SD), 0–110† 52.14 (20.78) 47.37 (19.92) 51.63 (20.19) 49.72 (21.44)
Smell test (UPSIT) score, mean (SD), 0–40† 14.08 (7.94) 13.67 (8.99) 12.80 (7.52) 16.02 (8.93)
Sense of smell loss (AM) score, mean (SD), 0–3† 2.76 (0.48) 2.68 (0.65) 2.79 (0.52) 2.65 (0.54)
LMK-CT score, mean (SD), 0–24† 18.28 (4.06) 18.63 (4.06) 19.07 (3.97) 17.15 (3.92)
TSS, mean (SD), 0–9† 7.21 (1.41) 6.99 (1.46) 7.29 (1.35) 6.92 (1.52)
Rhinosinusitis severity (VAS), mean (SD), 0–10 cm scale† 7.92 (2.09) 7.75 (2.02) 8.00 (2.00) 7.68 (2.18)
Blood eosinophils, mean (SD), median, Giga/L 0.44 (0.35), 0.36 0.42 (0.33), 0.33 0.47 (0.36), 0.37 0.37 (0.31), 0.29








Patients with comorbid asthma, n (%) 324 (60.2) 104 (55.9) 304 (66.2) 124 (46.8)
Patients with comorbid NSAID-ERD, n (%) 148 (27.5) 56 (30.1) 159 (34.6) 45 (17.0)
Patients with ≥1 prior sinonasal surgery, n (%) 292 (54.3) 167 (89.8) 459 (100.0) NA
Previous sinonasal surgeries, mean (SD) 1.97 (1.55) 1.93 (1.59) 1.96 (1.56) NA
Time since most recent sinonasal surgery, mean (SD), y 7.14 (6.35) 7.18 (6.60) 7.16 (6.44) NA
Time since last course of SCS use‡,§ mean (SD), d 216.75 (186.45) NA 216.60 (181.49) 216.95 (193.70)
Patients with SCS use in the previous 2 y, n (%) 538 (100) NA 292 (63.6) 246 (92.8)
Number of SCS courses in the previous 2 y, mean (SD) 1.55 (1.19) NA 1.69 (1.40) 1.39 (0.85)
TSS is a composite severity score consisting of the sum of daily symptoms of NC, loss of smell, and anterior/posterior rhinorrhoea. MCID for SNOT-22 
score is 8.9. † Higher mean scores indicate more severe disease, except for UPSIT score where lower mean scores indicate more severe disease. ‡ Data 
are based on the pooled population: all patients randomised to dupilumab 300 mg either q2w or q2w–q4w. § Number of patients with ≥1 day of SCS 
use and complete end dates reported. AM: morning, CT: computed tomography, d: day, LMK: Lund-Mackay, MCID: minimum clinically important dif-
ference, NC: nasal congestion, NP: nasal polyps, NPS: nasal polyp score, NSAID-ERD: non-steroidal anti-inflammatory drug-exacerbated respiratory 
disease, q2w: every 2 weeks, q4w: every 4 weeks, SNOT-22: 22-item Sino-Nasal Outcomes Test, SCS: systemic corticosteroid, SD: standard deviation, 
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the last SCS course. The mean number of SCS courses over the 
previous 2 years was 1.55. Further details on SCS use history are 
provided in Tables E2 and E3. 
Sinonasal surgery and SCS use requirements during the study
Dupilumab significantly reduced the number of patients who 
planned/underwent sinonasal surgery versus placebo during 
the treatment period by 82.6% (HR, 95% confidence interval 
[CI] versus placebo 0.174 [0.066, 0.462]; p=0.0005) with 5 (1.1%) 
patients receiving dupilumab requiring surgery compared with 
22 (7.7%) patients receiving placebo. Dupilumab reduced the 
Figure 2. Need for (A) sinonasal surgery – pooled ITT and (B–D) SCS use during the treatment period: (B) dupilumab q2w– pooled ITT; (C) dupilumab 
q2w and q2w-q4w – SINUS-52 ITT; (D) dupilumab q2w and q2w-q4w – pooled ITT. *p<0.05, **p<0.01, ***p<0.0001. HR was derived from a Cox 
proportional hazard model with the event of first sinonasal surgery (planned or actual, whichever came first) or SCS use as the response variable 
and treatment, asthma/NSAID-ERD status, region (pooled country) and study indicator (EFC14280=0 and EFC14146=1) as covariates. CI: confidence 
interval, HR: hazard ratio, ITT: intention-to-treat,  K-M: Kaplan-Meier, NE: not estimable, NSAID-ERD: non-steroidal anti-inflammatory drug-exacerbated 
respiratory disease, q2w: every 2 weeks, q4w: every 4 weeks, SCS: systemic corticosteroid. 
sinonasal surgery rate irrespective of prior sinonasal surgery or 
prior SCS use within the last 2 years (Figure 2A). In patients with 
a history of prior sinonasal surgery, 4 (1.5%) patients receiving 
dupilumab required sinonasal surgery during the study compa-
red with 15 (8.0%) patients receiving placebo.
Dupilumab also significantly reduced the need for SCS use 
versus placebo during the treatment period by 73.9% (HR, 95% 
CI versus placebo 0.261 [0.179, 0.379]; p<0.0001) (Figure 2B) and 
reduced the number of SCS courses by 75.3% (relative risk [RR] 
[95% CI] 0.247 [0.167, 0.365]; nominal p<0.0001). 
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Figure 3. Need for SCS use during the treatment period in patients (A) 
with and (B) without prior sinonasal surgery – pooled ITT. ITT: intention-
to-treat, K-M: Kaplan-Meier, q2w: every 2 weeks, SCS, systemic corticos-
teroid.
during the treatment period compared with those receiving 
placebo (41 [9.4%] and 88 [30.8%] patients, respectively). The 
mean (standard deviation [SD]) number of SCS courses during 
the treatment period was also lower in patients treated with 
dupilumab (0.21 [0.79] and 0.84 [1.88] for the dupilumab and 
placebo groups, respectively). The main reason for SCS use in 
both the dupilumab and placebo groups was for the relief of NP 
symptoms (15/41 [36.6% of all patients who received SCSs] and 
60/88 [68.2% of all patients who received SCSs] patients with 
dupilumab and placebo, respectively). Other reasons for SCS 
use in patients receiving dupilumab/placebo included asthma 
(8 [19. 5%]/17 [19.3%] patients), other respiratory disease (6 
[14.6%]/12 [13.6%] patients), other ear, nose or throat disease (2 
[4.9%]/12 [13.6%] patients), and any other reason (17 [41.5%]/6 
[6.8%] patients). The annualised SCS dose, duration and number 
of SCS courses for dupilumab versus placebo during the treat-
ment period were 60.5 mg vs. 209.5 mg, 2.6 days vs. 7.2 days and 
0.2 courses vs. 0.8 courses, respectively. 
The reduction in SCS use during the treatment period in pa-
tients receiving dupilumab versus placebo was evident irrespec-
tive of a history of prior surgery (Figure 2B/ Figure 3/Table E4) or 
prior SCS use (Figure 2B/ Figure 4/Table  E5). Similar reductions 
in SCS use were seen with dupilumab 300 mg q2w and 300 mg 
q2w-q4w versus placebo in the SINUS-52 ITT population (Figure 
2C) and in the pooled ITT population (Figure 2D).
Among the 129 patients with SCS use during the study, 17 
(13.2%) underwent sinonasal surgery during the study (pla-
cebo, n = 13/88 [14.8%]; dupilumab, n = 4/41 [9.8%]). Of the 27 
patients who required sinonasal surgery during the study, 17 
(63.0%) also needed SCS during the study (placebo, n = 13/22 
[59.1%]; dupilumab, n = 4/5 [80.0%]).
Results of sensitivity analyses, which included all data collected 
after SCS use, were consistent with the primary analysis (Table 
E6). The approaches used (WOCF/MI; mixed effect model with 
repeat measures; and ‘as-observed’ analyses including data 
after SCS use) were highly significant in favour of dupilumab (all 
p<0.0001) supporting the efficacy of dupilumab over current 
standard of care. 
Sinonasal outcomes in subgroups with/without SCS use and 
Figure 4. Need for SCS use during the treatment period in patients (A) 
with and (B) without SCS use – pooled ITT.  ITT: intention-to-treat, K-M: 
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Figure 5. Effect of dupilumab on (A) NPS, (B) NC score, (C) LMK-CT score, (D) SNOT-22 score and (E) UPSIT score at Week 24 in patients with/without 
SCS use, and with/without prior sinonasal surgery. *p<0.05, **p<0.01, ***p<0.0001. Efficacy endpoints were prospectively defined, and multiplicity 
adjusted and analysed using a hybrid method of WOCF and MI.  CI: confidence interval, CT: computed tomography, ITT: intention-to-treat, LMK: Lund-
Mackay, LS: least squares, MI: multiple imputation, NC: nasal congestion, NPS: nasal polyp score, SNOT-22: 22-item Sino-Nasal Outcomes Test, SCS: 
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with/without prior sinonasal surgery
At baseline, NPS, NC score and LMK-CT score were similar 
among patients regardless of history of SCS use in the previous 
2 years or prior sinonasal surgery (Table 1). Dupilumab consis-
tently improved NPS and NC and LMK-CT scores versus placebo 
in patients with/without prior SCS use, and with/without prior 
sinonasal surgery (Figure 5A–C). Significant improvements ver-
sus placebo were also observed for SNOT-22 and UPSIT scores 
(Figure 5D, E). A total of 379 (84.2%)/172 (66.2%) patients with/
without surgery were anosmic at baseline with an UPSIT score 
of ≤18. This was reduced to 234 (53.4%)/95 (37.3%) patients at 
Week 24. 
Safety
Dupilumab was generally well tolerated. Non-fatal serious AEs 
occurred in 16/282 patients (5.7%) receiving placebo and 15/440 
patients (3.4%) receiving dupilumab. Common AEs (in ≥5% of 
patients) were nasopharyngitis, headache, worsening NP and 
asthma, epistaxis and injection-site erythema, all of which oc-
curred with higher frequency in placebo-treated patients. An 
overview of treatment-emergent AEs can be found in Table E7.
Discussion
The patients enrolled in SINUS-24 and SINUS-52 represented 
a population of adults with severe CRSwNP, as reflected by 
baseline characteristics of large polyps, severe symptoms, ex-
tensive bilateral sinus disease evidence on a CT scan, profoundly 
impaired sense of smell and substandard HRQoL. Their disease 
was inadequately controlled despite receiving the recommen-
ded standard of care, including INCS, SCSs and/or sinonasal 
surgery. Nearly three-quarters of patients (74%) had received 
SCSs with an average of 1.55 courses in the previous 2 years and 
almost two-thirds (63.4%) of patients had a history of sinonasal 
surgery throughout their lifetime with a mean of approximately 
2 previous surgeries. These patients with uncontrolled disease 
responded well to dupilumab, and, remarkably, the magnitude 
of treatment effect was similar in patients with previous SCS tre-
atment and/or sinonasal surgery (indicating refractory disease) 
compared with those who had not received such treatments 
previously. This demonstrates that dupilumab treatment for 
CRSwNP leads to consistent and clinically meaningful improve-
ments in sinonasal outcome measures irrespective of previous 
therapy or surgery. Sensitivity analyses (including data collected 
after rescue SCS use) were consistent with the primary analysis 
results and further support the superior efficacy of dupilumab 
over standard of care including topical and systemic corticoste-
roids. In addition, 84.2% of patients who had previous sinonasal 
surgery were anosmic at baseline, but this was reduced to 53.4% 
of patients at Week 24 following dupilumab treatment. The 
overall improvement in sense of smell (UPSIT score) at Week 24 
in patients receiving dupilumab versus placebo was 10.57. 
CRSwNP is a chronic predominantly type 2 inflammatory disease 
mediated by the key cytokines IL-4, IL-13 and IL-5, with in nasal 
polyp infiltration by eosinophils, basophils and mast cells(21). 
Standard of care therapeutic options for patients with CRSwNP 
are often inadequate to achieve sustained disease control, as 
they do not always address the underlying type 2 inflammation. 
The existing treatment paradigm of frequent courses of SCS 
use (up to 3 before surgery is recommended) and/or recurrent 
surgeries results in high morbidity and inadequately controlled 
symptoms. This highlights the need for a shift towards a more 
holistic approach to CRSwNP management. Furthermore, other 
type 2 diseases such as asthma and AERD or N-ERD that are fre-
quent comorbidities in patients with CRSwNP may also benefit 
from such treatment. These patients tend to have more severe 
CRSwNP disease, characterised by high NP recurrence rates after 
surgery and, often, corticosteroid dependence(4,22). Similarly, pa-
tients with uncontrolled asthma who also have NP could benefit 
from treatment with dupilumab. 
The SINUS studies were designed to evaluate the treatment 
effects of dupilumab in ‘real-world’ clinical settings and permit-
ted the use of SCSs and surgery at the discretion of the treating 
investigators. The results showed a substantial steroid sparing 
effect of dupilumab with almost 74% reduction, relative to 
placebo (who received daily INCS), in the number of patients re-
quiring SCS rescue use. The adjusted annualised total number of 
SCS courses was reduced by ~75%. Dupilumab also reduced the 
sinonasal surgery rate by 82.6% in the overall population. In ad-
dition, dupilumab showed similar significant effects in NPS and 
NC and LMK-CT scores across all settings including in patients 
with prior surgery(20).
Multiple studies have demonstrated the significant undesirable 
effects of SCS use. Even with intermittent oral corticosteroid use, 
it has been shown that patients are at increased risk for sepsis, 
thromboembolism, osteopenia and fractures(23–25). There is also 
evidence to suggest that suppression of cell-mediated immunity 
by corticosteroids can lead to recurrent viral infections, pneu-
monia and atypical bacterial infections such as tuberculosis(10). 
Surgical treatment options are considered relatively safe but are 
not completely without risks and can be associated with minor 
(reported incidence of 1.1–20.8%) and major (0–1.5%) risks such 
as severe bleeding or infection, and orbital/cranial damage(26), 
as well as heightened risk of nosocomial infections(27). Evolving 
concerns about surgery now also include the safety of personnel 
from aerosols generated during surgery and nasal endoscopy(28). 
Traditional concerns about risks of immune suppression are also 
heightened in the context of widespread infection.
Dupilumab, thus, has the potential to reduce the risks associ-
ated with frequent and chronic use of SCS and with surgical 
procedures while also significantly restoring sense of smell, 
one of the most troublesome and difficult to treat symptoms 
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weeks with dupilumab in the need for SCS use and/or sinonasal 
surgery reported here, along with the improvement in CRSwNP 
symptoms, demonstrates the suitability of dupilumab as a 
long-term treatment option in patients with severe CRSwNP. 
In the 1-year treatment period of SINUS-52, dupilumab did not 
increase overall infection rates compared with placebo and was 
associated with lower rates of respiratory infections in patients 
with CRSwNP(29).
The anti-IL-5 treatment, mepolizumab, is currently under 
investigation for treatment of eosinophilic NP. In patients with 
persistent NP treated with mepolizumab, a reduction in the 
proportion of patients that met the criteria for surgery has been 
reported, without providing the rate of reduction in true surgery 
or SCS use (16 [30%] of patients receiving mepolizumab versus 5 
[10%] patients receiving placebo no longer meeting the criteria; 
p=0.006)(30). Two recent phase 3 studies with the anti-IgE biolo-
gic omalizumab were completed and showed some reduction 
in SCS use (62.5% relative reduction) and surgery need (defined 
by patients achieving NPS ≤4 and a change of ≥8.9 in SNOT-22 
score) without reaching statistical significance; however, a very 
limited number of patients received SCSs or needed sinonasal 
surgery in both the placebo and omalizumab arms (8 [6.2%] and 
3 [2.3%] patients, respectively; p=0.16)(31,32). The use of biologics 
may pose a significant economic burden on healthcare systems 
and requires careful selection of patients. On the other hand, 
high costs are also associated with surgical treatment and SCS 
use in patients with CRSwNP, particularly in those with comorbid 
asthma(33–35). Additional healthcare costs linked to oral corti-
costeroid-induced AEs have also been documented in severe 
asthma patients(9). Dupilumab has the potential to provide on-
going disease control in CRSwNP, reducing the need for SCS use 
and sinonasal surgeries (with associated reduction in healthcare 
resource use), whilst improving HRQoL for patients through 
reduction of disease burden and improvement of symptoms.
A potential limitation of this current dupilumab analysis is that 
the type of sinonasal surgery prior to enrolment was not speci-
fied for participation in the trial which may have had an impact 
on the characteristics of the study population at baseline. In 
addition to this, the criteria for the need for SCS use and surgery 
and the dose and duration of SCS use were decided by the tre-
ating physicians. While this has the advantage to reflect real-life 
use, it may have caused variability in results, as such decisions 
may vary depending on the experience and judgement of the 
individual physician. 
Dupilumab treatment was generally well tolerated. Common 
AEs (in ≥5% of patients) in the pooled safety population were 
nasopharyngitis, headache, worsening NP and asthma, epistaxis 
and injection-site erythema, all of which occurred with higher 
frequency in placebo-treated patients.
Conclusion
The results presented here suggest that dupilumab, as a con-
tinuous treatment that targets the key and central drivers of 
type 2 inflammation in CRSwNP, has the potential to provide 
continuous disease control, reduce the need for SCS use and 
sinonasal surgeries, bring about effective improvements in 
HRQoL and restore olfactory function.
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Dupilumab reduces SCS use and surgery in CRSwNP
TSS is a composite severity score consisting of the sum of daily symptoms of NC, loss of smell, and anterior/posterior rhinorrhoea. MCID for SNOT-22 
score is 8.9. † Higher mean scores indicate more severe disease, except for UPSIT score where lower mean scores indicate more severe disease. ‡ Data 
are based on the pooled population: all patients randomised to dupilumab 300 mg either q2w or q2w–q4w. § Number of patients with ≥1 day of SCS 
use and complete end dates reported. AM: morning, CT: computed tomography, d: day, IgE: immunoglobulin E, LMK: Lund-Mackay, MCID: minimum 
clinically important difference, NC: nasal congestion, NP: nasal polyps, NPS: nasal polyp score, NSAID-ERD: non-steroidal anti-inflammatory drug-
exacerbated respiratory disease, q2w: every 2 weeks, q4w: every 4 weeks, SNOT-22: 22-item Sino-Nasal Outcomes Test, SCS: systemic corticosteroid, 
SD: standard deviation, TSS: total symptom score, UPSIT: University of Pennsylvania Smell Identification Test, VAS: visual analogue scale: y, year. 
SUPPLEMENTARY DATA
Table E1. Baseline characteristics for patients with/without prior SCS use or with/without prior sinonasal surgery by treatment group.
Characteristic Placebo (n=286) Dupilumab 300 mg 
q2w (n=438)







































Male sex, n (%) 124 (59.3) 41 (53.2) 214 (65.0) 58 (53.2) 103 (55.1) 62 (62.6) 165 (60.7) 107 (64.5)
NP duration, mean (SD), y 10.35 (8.99) 12.12 (8.97) 10.05 (9.49) 14.32 (9.78) 13.75 (9.16) 5.37 (5.54) 14.51 (9.93) 5.63 (6.30)
Bilateral endoscopic NPS, mean 
(SD), 0–8† 
5.95 (1.24) 5.82 (1.30) 6.05 (1.27) 5.87 (1.17) 5.74 (1.27) 6.24 (1.18) 5.94 (1.26) 6.10 (1.22)
Nasal congestion (AM) score, 
mean (SD), 0–3† 
2.45 (0.53) 2.32 (0.58) 2.41 (0.59) 2.36 (0.63) 2.47 (0.53) 2.30 (0.56) 2.42 (0.59) 2.35 (0.63)


















Smell test (UPSIT) score, mean 
(SD), 0–40†
14.19 (8.03) 13.80 (9.07) 14.01 (7.89) 13.57 (8.97) 13.01 (7.46) 16.13 (9.39) 12.65 (7.57) 15.95 (8.68)
Sense of smell loss (AM) score, 
mean (SD), 0–3†
2.77 (0.45) 2.61 (0.66) 2.75 (0.51) 2.73 (0.64) 2.77 (0.48) 2.63 (0.57) 2.80 (0.55) 2.66 (0.52)
LMK-CT score, mean (SD), 0–24† 18.54 (4.09) 18.51 (4.18) 18.11 (4.04) 18.72 (3.99) 19.16 (4.10) 17.34 (3.86) 19.01 (3.89) 17.04 (3.97)
TSS, mean (SD), 0–9† 7.27 (1.35) 6.91 (1.47) 7.18 (1.45) 7.04 (1.46) 7.36 (1.29) 6.83 (1.51) 7.25 (1.39) 6.98 (1.54)
Rhinosinusitis severity (VAS), 
mean (SD), 0–10 cm scale†
8.08 (2.12) 7.65 (2.18) 7.82 (2.06) 7.82 (1.91) 8.10 (2.00) 7.73 (2.37) 7.92 (2.00) 7.65 (2.06)












































Patients with comorbid asthma, 
n (%)
130 (62.2) 40 (51.9) 194 (59.0) 64 (58.7) 121 (64.7) 49 (49.5) 183 (67.3) 75 (45.2)
Patients with comorbid NSAID-
ERD, n (%)
64 (30.6) 18 (23.4) 84 (25.5) 38 (34.9) 65 (34.8) 17 (17.2) 94 (34.6) 28 (16.9)
Patients with ≥1 prior sinonasal 
surgery, n (%)
118 (100) 69 (100) 174 (100) 98 (100) 187 (100) 0 272 (100) 0
Previous sinonasal surgeries, 
mean (SD)
2.02 (1.48) 1.86 (1.41) 1.94 (1.59) 1.99 (1.72) 1.96 (1.45) 0 1.96 (1.64) 0
Time since most recent sinona-
sal surgery, mean (SD), y 
7.10 (6.20) 6.99 (6.59) 7.17 (6.47) 7.31 (6.65) 7.06 (6.33) NA 7.22 (6.52) NA
Time since last course of SCS 















Patients with SCS use in the 
previous 2 y, n (%)
209 (100) 0 329 (100) 0 118 (63.1) 91 (91.9) 174 (64.0) 155 (93.4)
Number of SCS courses in the 
previous 2 y, mean (SD)
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Table E2. SINUS-24 and SINUS-52: History of SCS use at baseline, number of courses.
SINUS-24: ITT SINUS-52: ITT
Placebo (n=133) Dupilumab 300 mg 
q2w (n=143)
Placebo (n=153) Dupilumab 300 mg 
q2w–q4w (n=145)
Dupilumab 300 mg 
q2w (n=150)
Patients with SCS use in the 
previous year † n (%)
71 (53.4) 77 (53.8) 101 (66.0) 91 (62.8) 97 (64.7)
1 course 55 (77.5) 60 (77.9) 80 (79.2) 67 (73.6) 75 (77.3)
2 courses 12 (16.9) 11 (14.3) 17 (16.8) 13 (14.3) 13 (13.4)
3 courses 4 (5.6) 6 (7.8) 2 (2.0) 5 (5.5) 3 (3.1)
4 courses 0 0 1 (1.0) 0 4 (4.1)
≥5 courses 0 0 1 (1.0) 6 (6.6) 2 (2.1)
SCS courses in the prior year
Mean (SD) 1.28 (0.57) 1.30 (0.61) 1.28 (0.65) 1.58 (1.32) 1.41 (0.94)
Median 1.00 1.00 1.00 1.00 1.00
 
† A course of SCS is considered continuous if treatment is separated by less than 7 days. ITT: intention-to-treat, q2w: every 2 weeks, q4w: every 4 
weeks, SCS: systemic corticosteroid, SD: standard deviation.
 Table E3. SINUS-24 and SINUS-52: History of SCS use at baseline, no. of days.
SINUS-24: ITT SINUS-52: ITT
Placebo (n=133) Dupilumab 300 mg 
q2w (n=143)
Placebo (n=153) Dupilumab 300 mg 
q2w–q4w (n=145)
Dupilumab 300 mg 
q2w (n=150)
Days with SCS use during the 
last year
Number † (%) 43 (32.3) 52 (36.4) 63 (41.2) 45 (31.0) 55 (36.7)
Mean (SD) 11.58 (9.41) 13.48 (18.32) 13.05 (11.53) 42.84 (83.64) 46.15 (84.24)
Median 10.00 10.00 8.00 14.00 12.00
Number ‡ (%) 71 (53.4) 77 (53.8) 101 (66.0) 91 (62.8) 97 (64.7)
0–7 days 17/71 (23.9) 15/77 (19.5) 26/101 (25.7) 11/91 (12.1) 13/97 (13.4)
8–14 days 16/71 (22.5) 25/77 (32.5) 21/101 (20.8) 12/91 (13.2) 19/97 (19.6)
15–21 days 5/71 (7.0) 8/77 (10.4) 3/101 (3.0) 6/91 (6.6) 9/97 (9.3)
22–28 days 3/71 (4.2) 2/77 (2.6) 3/101 (3.0) 3/91 (3.3) 1/97 (1.0)
29–56 days 2/71 (2.8) 1/77 (1.3) 10/101 (9.9) 7/91 (7.7) 4/97 (4.1)
57–84 days 0/71 0/77 0/101 0/91 2/97 (2.1)
85–112 days 0/71 0/77 0/101 2/91 (2.2) 0/97
>112 8/71 (11.3) 6/77 (7.8) 5/101 (5.0) 11/91 (12.1) 13/97 (13.4)
Undetermined duration 20/71 (28.2) 20/77 (26.0) 33/101 (32.7) 39/91 (42.9) 36/97 (37.1)
† Number of patients with ≥1 day of SCS use and complete dates reported. ‡ Number of patients with ≥1 day of SCS use. ITT: intention-to-treat, q2w: 
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Table E4. Proportion of patients with SCS use during treatment period in patients with/without prior sinonasal surgery – pooled ITT.
With prior sinonasal surgery Without prior sinonasal surgery
Placebo 
(n=187)




Dupilumab 300 mg q2w 
(n=166)
Patients with SCS, n (%) 55 (29.4) 24 (8.8) 33 (33.3) 17 (10.2)
Kaplan-Meier estimates for probability of 
a patient with ≥1 event (95% CI) up to




































P value vs. placebo† <0.0001 <0.0001
† HR derived from Cox proportional hazard model with the event of first SCS as the response variable and treatment, asthma/NSAID-ERD status, prior 
surgery history, region (pooled country), and study indicator (EFC14280=0 and EFC14146=1) as covariates.  CI: confidence interval, HR: hazard ratio, 
ITT: intention-to-treat, NSAID-ERD: non-steroidal anti-inflammatory drug-exacerbated respiratory disease, q2w: every 2 weeks, SCS: systemic corticos-
teroid.
Table E5. Proportion of patients with SCS use during treatment period – patients with/without SCS use.
With prior SCS use Without prior SCS use
Placebo (n=209) Dupilumab 300 mg q2w 
(n=329)
Placebo (n=77) Dupilumab 300 mg q2w 
(n=109)
Patients with SCS, n (%) 76 (36.4) 37 (11.2) 12 (15.6) 4 (3.7)
Kaplan-Meier estimates for probability of 
a patient with ≥1 event (95% CI) up to




































p value vs. placebo† <0.0001 0.0051
† HR derived from Cox proportional hazard model with the event of first SCS as the response variable and treatment, asthma/NSAID-ERD status, prior 
surgery history, region (pooled country), and study indicator (EFC14280=0 and EFC14146=1) as covariates. CI: confidence interval, HR: hazard ratio, 
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Table E6. Sensitivity analysis of primary endpoints: ‘as-observed’ data including all data collected after SCS use.
Primary endpoints 
(LS mean change 








LS mean difference 






LS mean difference 
dupilumab vs. placebo 
(95% CI)
Bilateral NPS 
    WOCF/MI 0.17 (0.15) −1.89 (0.14) −2.06 (−2.43, −1.69)*** 0.10 (0.14) −1.71 (0.11) −1.80 (−2.10, −1.51)***
    MMRM† 0.11 (0.16) −2.02 (0.14) −2.13 (−2.52, −1.73)*** 0.06 (0.15) −1.78 (0.10) −1.83 (−2.16, −1.51)***
    As-observed 
analysis
0.09 (0.15) −1.90 (0.14) −1.98 (−2.35, −1.61)*** −0.05 (0.14) −1.83 (0.11) −1.77 (−2.07, −1.47)***
NC
    WOCF/MI −0.45 (0.07) −1.34 (0.07) −0.89 (−1.07, −0.71) *** −0.38 (0.07) −1.25 (0.06) −0.87 (−1.03, −0.71)***
    MMRM† −0.53 (0.07) −1.41 (0.06) −0.88 (−1.05, −0.70)*** −0.51 (0.07) −1.34 (0.05) −0.82 (−0.99, −0.65)***
    As-observed 
analysis
−0.56 (0.07) −1.38 (0.07) −0.82 (−1.00, −0.65)*** −0.48 (0.07) −1.28 (0.06) −0.80 (−0.95, −0.64)***
LMK-CT score
   WOCF/MI −0.74 (0.37) −8.18 (0.34) −7.44 (−8.35, −6.53) *** −0.09 (0.31) −5.21 (0.24) −5.13 (−5.80, −4.46)***
   MMRM† −1.15 (0.40) −8.72 (0.34) −7.57 (−8.53, −6.61)*** −0.33 (0.35) −5.54 (0.24) −5.21 (−5.97, −4.45)***
   As-observed 
analysis
−1.09 (0.37) −8.40 (0.34) −7.32 (−8.22, −6.41)*** −0.47 (0.30) −5.55 (0.23) −5.09 (−5.75, −4.43)***
***p<0.0001. † For MMRM approaches, for patients who underwent surgery for NP or received SCSs for any reason, data collected post-surgery or 
post-SCS use was set to missing. CI: confidence interval, CT: computed tomography, LS: least squares, LMK: Lund-Mackay, MMRM: mixed effect model 
with repeated measurements, NC: nasal congestion, NPS: nasal polyp score, SCS: systemic corticosteroid, SE: standard error, WOCF/MI: worst observa-
tion carried forward/multiple imputation.
Table E7. Overview of TEAEs: pooled analysis of SINUS-24 and SINUS-52.
Patients with TEAE†, n (%) Randomised treatment
Placebo (n=282) Dupilumab 300 mg q2w (n=440)
Any TEAE 208 (73.8) 305 (69.3)
Any serious TEAE 16 (5.7) 15 (3.4)
Any TEAE leading to death† 0 0
Any TEAE leading to permanent treatment 
discontinuation
15 (5.3) 11 (2.5)
TEAEs occurring in ≥5% of patients (MedDRA PT)
Nasopharyngitis 41 (14.5) 55 (12.5)
Headache 24 (8.5) 32 (7.3)
Epistaxis 20 (7.1) 25 (5.7)
Nasal polyps 33 (11.7) 12 (2.7)
Asthma 20 (7.1) 7 (1.6)
Injection-site erythema 22 (7.8) 28 (6.4)
† Defined as events occurring from the time of signed informed consent until the end of the study by MedDRA PT. MedDRA: Medical Dictionary of 
Regulatory Activities, PT: preferred term, q2w: every 2 weeks, TEAE: treatment-emergent adverse event.
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